PMC10140560_01
PMC10140560_02
Dynamics of PANSS negative subscale values in the course of therapy with Cariprazine.
fpsyt-14-1155518-g001.jpg
PMC10140560_02_fpsyt-14-1155518-g001.jpg
fig1
After 18 months of Cariprazine - at a 4.5 mg daily dose, the positive subscale of PANSS showed relatively no significant change, but the negative subscale mean score decreased by 29.8% (Figure 1).
Dynamics of the overall PANSS mean score in the course of therapy with Cariprazine.
fpsyt-14-1155518-g002.jpg
PMC10140560_02_fpsyt-14-1155518-g002.jpg
fig2
The overall PANSS mean score decreased by 23.8% (Figure 2), CGI-S mean score improved by 25%, and the mean GAF score increased by 29.5% (Figure 3).
Dynamics of the mean GAF scores in the course of therapy with Cariprazine.
fpsyt-14-1155518-g003.jpg
PMC10140560_02_fpsyt-14-1155518-g003.jpg
fig3
The overall PANSS mean score decreased by 23.8% (Figure 2), CGI-S mean score improved by 25%, and the mean GAF score increased by 29.5% (Figure 3).